What is Zacks Research’s Estimate for Chemours Q3 Earnings?

The Chemours Company (NYSE:CC) – Investment analysts at Zacks Research reduced their Q3 2026 EPS estimates for shares of Chemours in a research report issued to clients and investors on Tuesday, August 18th. Zacks Research analyst Team now forecasts that the specialty chemicals company will earn $0.25 per share for the quarter, down from their prior forecast of $0.41. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $0.87 per share. Zacks Research also issued estimates for Chemours’ Q1 2027 earnings at $0.40 EPS, Q3 2027 earnings at $0.58 EPS and FY2028 earnings at $2.31 EPS.

A number of other research analysts have also recently issued reports on CC. JPMorgan Chase & Co. dropped their target price on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 13th. Weiss Ratings cut Chemours from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, August 6th. Royal Bank Of Canada lowered their price target on Chemours from $26.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $17.00 price objective on shares of Chemours in a research note on Thursday, August 13th. Finally, BMO Capital Markets reduced their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $20.10.

Chemours Stock Down 1.1%

CC stock opened at $15.74 on Friday. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. The company’s 50-day moving average price is $18.14 and its 200 day moving average price is $20.04. Chemours has a 52 week low of $10.44 and a 52 week high of $28.67. The company has a market cap of $2.37 billion, a P/E ratio of -8.24 and a beta of 1.43.

Chemours (NYSE:CC) last announced its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter last year, the business earned ($2.54) EPS. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be given a dividend of $0.0875 per share. The ex-dividend date is Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a yield of 2.2%. Chemours’s payout ratio is presently -18.32%.

Insiders Place Their Bets

In other Chemours news, insider Calderon Gerardo Familiar purchased 1,935 shares of the stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the transaction, the insider directly owned 58,547 shares of the company’s stock, valued at $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Shane Hostetter acquired 3,350 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average cost of $14.94 per share, with a total value of $50,049.00. Following the completion of the purchase, the chief financial officer owned 102,698 shares in the company, valued at approximately $1,534,308.12. This represents a 3.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 8,663 shares of company stock worth $130,601. Insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Chemours

Institutional investors and hedge funds have recently bought and sold shares of the stock. Baird Financial Group Inc. acquired a new stake in Chemours during the 1st quarter valued at $148,000. Royal Bank of Canada raised its holdings in shares of Chemours by 6.8% in the first quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company’s stock worth $7,926,000 after acquiring an additional 37,382 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Chemours in the first quarter worth $161,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Chemours by 149.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company’s stock valued at $593,000 after acquiring an additional 25,899 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in shares of Chemours in the first quarter valued at $403,000. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks raised its EPS forecasts for Q1 2027 to $0.40 from $0.39, Q3 2027 to $0.58 from $0.56, FY2027 to $2.05 from $1.95, Q4 2027 to $0.61 from $0.53, Q1 2028 to $0.56 from $0.55, and Q2 2028 to $0.65 from $0.61. These revisions suggest some confidence in Chemours’ longer-term earnings recovery. Analysts Offer Insights on Materials Companies: Chemours Company (CC) and Solstice Advanced Materials, Inc. (SOLS)
• Neutral Sentiment: The analyst changes are uneven rather than uniformly bullish: select estimates for 2027 and 2028 increased, while several near-term forecasts declined. Zacks’ current full-year EPS consensus is approximately $0.87-$0.88.
• Negative Sentiment: Zacks cut its Q3 2026 EPS estimate sharply to $0.25 from $0.41 and reduced its FY2026 forecast to $0.83 from $0.90. Q4 2026 EPS was also lowered to $0.11 from $0.12, indicating weaker expected results in the nearer term. The continued “Strong Sell” rating is likely weighing on investor sentiment.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.